5-ethyl-octanoic acid | 873392-84-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-ethyl-octanoic acid
• 英文别名: 5-Aethyl-octansaeure；5-Ethyloctanoic acid
• CAS: 873392-84-8
• 化学式: C₁₀H₂₀O₂
• 分子量: 172.268
• InChiKey: WKUXGLNXSMUSTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-ethyl-octanoic acid 在 氯化亚砜 作用下， 生成 5-ethyl-octanoyl chloride
  参考文献：
  名称：

  Badger et al., Journal of the Chemical Society, 1954, p. 4162,4165

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-二甲基噻吩 在 氢氧化钾 、 三氯化铝 、 sodium carbonate 、 一水合肼 、 硝基苯 、 二乙二醇 作用下， 生成 5-ethyl-octanoic acid
  参考文献：
  名称：

  Badger et al., Journal of the Chemical Society, 1954, p. 4162,4165

  摘要：

  DOI：

文献信息

• Methods for the synthesis of milnacipran and congeners thereof
  申请人：Buchwald L. Stephen

  公开号：US20050282898A1

  公开（公告）日：2005-12-22

  One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof.

  本发明的一个方面涉及合成米纳西普兰或其同系物的方法。本发明的另一个方面涉及不对称方法合成对映富集的米纳西普兰或其同系物。本发明还涉及合成中间体的方法，该中间体在合成不对称或对称的对映富集的米纳西普兰或其同系物的方法中有用。
• Process for producing alpha-olefin polymer
  申请人：Tosoh Corporation

  公开号：EP0648786A1

  公开（公告）日：1995-04-19

  A catalyst for olefin polymerization is provided which comprises, as the components, a) a metallocene compound, b) an ionizing ionic compound, c) an organoaluminum compound, and d) a Lewis base compound. This catalyst has a stable active species and improves productivity of an olefin polymer without deterioration of the catalytic activity.

  本发明提供了一种用于烯烃聚合的催化剂，其组分包括：a) 茂金属化合物；b) 电离离子化合物；c) 有机铝化合物；d) 路易斯碱化合物。这种催化剂具有稳定的活性物种，可提高烯烃聚合物的生产率，而不会降低催化活性。
• INSOLUBLE INSULIN COMPOSITIONS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0911035A2

  公开（公告）日：1999-04-28

  The present invention relates to insoluble compositions containing acylated proteins selected from the group consisting of acylated insulin, acylated insulin analog, and acylated proinsulin, and formulations thereof. The formulations are suitable for parenteral delivery or other means of delivery, to a patient for extended control of blood glucose levels. More particularly, the present invention relates to compositions comprised of an acylated protein complexed with zinc, protamine, and a phenolic compound such that the resulting microcrystal is analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that compositions of such acylated proteins have therapeutically superior subcutaneous release pharmacokinetics, and more extended and flatter glucodynamics, than presently available commercial preparations of NPH insulin. Yet, the present crystals retain certain advantageous properties of NPH crystals, being readily able to be resuspended and also mixable with soluble insulins.

  本发明涉及含有选自由酰化胰岛素、酰化胰岛素类似物和酰化原胰岛素组成的组中的酰化蛋白质的不溶性组合物及其制剂。这些制剂适用于肠道外给药或以其他方式给药，以延长对患者血糖水平的控制。更具体地说，本发明涉及一种由酰化蛋白质与锌、原胺和酚类化合物络合而成的组合物，由此产生的微晶类似于中性原胺哈格多恩（NPH）胰岛素晶型。令人惊奇的是，人们发现这种酰化蛋白质的组合物与目前市售的 NPH 胰岛素商业制剂相比，具有更优越的皮下释放药代动力学和更持久、更平稳的血糖动力学。然而，目前的晶体仍保留了 NPH 晶体的某些有利特性，易于重新悬浮，也可与可溶性胰岛素混合。
• Insoluble compositions for controlling blood glucose
  申请人：ELI LILLY AND COMPANY

  公开号：EP0925792A2

  公开（公告）日：1999-06-30

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。
• Insoluble Insulin Compositions for Controlling Blood Glucose
  申请人：Eli Lilly & Company

  公开号：EP1396272A1

  公开（公告）日：2004-03-10

  The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

  本发明涉及不溶性组合物，该组合物包含选自由胰岛素、胰岛素类似物和原胰岛素组成的组的蛋白质；选自由衍生化胰岛素、衍生化胰岛素类似物和衍生化原胰岛素组成的组的衍生化蛋白质；复合物；六聚体稳定化合物；以及二价金属阳离子。不溶性组合物的制剂既适用于肠道外给药，也适用于治疗高血糖和糖尿病的非肠道外给药。不溶性沉淀物的微晶形式在药学上类似于中性原明哈格登（NPH）胰岛素晶体形式。令人惊奇的是，人们发现这种不溶性组合物的悬浮制剂具有独特的可控溶解特性，与 NPH 胰岛素制剂相比，这种悬浮制剂具有治疗上有利的血糖动力学特性。